|
1
|
Collisson EA, Campbell JD, Brooks AN,
Berger AH, Lee W, Chmielecki J, Beer DG, Cope L, Creighton CJ,
Danilova L, et al: Cancer Genome Atlas Research Network:
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kris MG, Johnson BE, Berry LD, Kwiatkowski
DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson
SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in
lung cancers to select targeted drugs. JAMA. 311:1998–2006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soucheray M, Capelletti M, Pulido I, Kuang
Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour
F, et al: Intratumoral heterogeneity in EGFR-Mutant NSCLC results
in divergent resistance mechanisms in response to EGFR tyrosine
kinase inhibition. Cancer Res. 75:4372–4383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oxnard GR, Paweletz CP, Kuang Y, Mach SL,
O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P,
Jackman DM, et al: Noninvasive detection of response and resistance
in EGFR-mutant lung cancer using quantitative next-generation
genotyping of cell-free plasma DNA. Clin Cancer Res. 20:1698–1705.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Diaz LA Jr and Bardelli A: Liquid
biopsies: Genotyping circulating tumor DNA. J Clin Oncol.
32:579–586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nagai Y, Miyazawa H, Huqun Tanaka T,
Udagawa K, Kato M, Fukuyama S, Yokote A, Kobayashi K, Kanazawa M,
et al: Genetic heterogeneity of the epidermal growth factor
receptor in non-small cell lung cancer cell lines revealed by a
rapid and sensitive detection system, the peptide nucleic
acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276–7282. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanaka T, Nagai Y, Miyazawa H, Koyama N,
Matsuoka S, Sutani A, Huqun Udagawa K, Murayama Y, Nagata M, et al:
Reliability of the peptide nucleic acid-locked nucleic acid
polymerase chain reaction clamp-based test for epidermal growth
factor receptor mutations integrated into the clinical practice for
non-small cell lung cancers. Cancer Sci. 98:246–252. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramirez RD, Sheridan S, Girard L, Sato M,
Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, et al:
Immortalization of human bronchial epithelial cells in the absence
of viral oncoproteins. Cancer Res. 64:9027–9034. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gandhi J, Zhang J, Xie Y, Soh J,
Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW,
et al: Alterations in genes of the EGFR signaling pathway and their
relationship to EGFR tyrosine kinase inhibitor sensitivity in lung
cancer cell lines. PLoS One. 4:e45762009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giacona MB, Ruben GC, Iczkowski KA, Roos
TB, Porter DM and Sorenson GD: Cell-free DNA in human blood plasma:
Length measurements in patients with pancreatic cancer and healthy
controls. Pancreas. 17:89–97. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heitzer E, Ulz P and Geigl JB: Circulating
tumor DNA as a liquid biopsy for cancer. Clin Chem. 61:112–123.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sikora A, Zimmermann BG, Rusterholz C,
Birri D, Kolla V, Lapaire O, Hoesli I, Kiefer V, Jackson L and Hahn
S: Detection of increased amounts of cell-free fetal DNA with short
PCR amplicons. Clin Chem. 56:136–138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weisenberger DJ, Trinh BN, Campan M,
Sharma S, Long TI, Ananthnarayan S, Liang G, Esteva FJ, Hortobagyi
GN, McCormick F, et al: DNA methylation analysis by digital
bisulfite genomic sequencing and digital MethyLight. Nucleic Acids
Res. 36:4689–4698. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hyman DM, Diamond EL, Vibat CR, Hassaine
L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, et
al: Prospective blinded study of BRAFV600E mutation detection in
cell-free DNA of patients with systemic histiocytic disorders.
Cancer Discov. 5:64–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Janku F, Vibat CR, Kosco K, Holley VR,
Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L,
Hassaine L, et al: BRAF V600E mutations in urine and plasma
cell-free DNA from patients with Erdheim-Chester disease.
Oncotarget. 5:3607–3610. 2014. View Article : Google Scholar : PubMed/NCBI
|
